Craig Wright

Craig Wright supports the Food and Drug Administration’s Office of Acquisition and Grant Services in executing strategic procurement actions critical to advancing regulatory science and public health. He manages acquisitions focused on scientific research, laboratory infrastructure, and high-precision analytical instrumentation, ensuring the FDA maintains the technical capacity to evaluate drug safety, efficacy, and medical device performance. His work directly enables the agency’s mission by securing specialized services that underpin preclinical and clinical research, toxicological analysis, and biotechnology innovation. Wright typically handles complex service-based contracts requiring deep scientific and regulatory alignment, often involving multi-year performance periods and stringent compliance requirements. He maintains consistent working relationships with niche scientific service providers, including Tranquil Clinical and Research Consulting Services LLC, Toxicologic Pathology Associates Inc., and Progenics Pharmaceuticals Inc., reflecting a preference for specialized vendors with proven expertise in preclinical research, toxicology, and pharmaceutical development. These partnerships are characterized by recurring engagements and long-term service delivery models, indicating a focus on continuity, technical reliability, and domain-specific compliance with FDA standards. His contracting approach emphasizes vendor qualifications in regulated environments and adherence to Good Laboratory Practices (GLP) and Good Clinical Practices (GCP). Wright’s procurement portfolio reflects a balanced approach to socioeconomic goals, with approximately one-third of awards designated as total small business set-asides under FAR 19.5, while the majority remain open competition. This pattern demonstrates a deliberate commitment to fostering small business participation without compromising access to specialized technical capabilities. He actively leverages small business programs to expand the vendor base in high-demand scientific service categories, ensuring competitive diversity while maintaining performance integrity. His primary procurement focus lies in NAICS 541714 (Research and Development in Biotechnology), where he secures advanced biotech R&D services including assay development, biomarker validation, and molecular characterization. He also procures social science research under NAICS 541720, supporting behavioral and policy studies relevant to drug utilization and public health outcomes. His technical domain expertise centers on regulated biopharmaceutical research, analytical method validation, and translational science services essential to FDA’s regulatory decision-making.